The Latest Breaking News from PBMs

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

A deal announced this week on a series of drug pricing bills could be a sign of progress an issue that has bedeviled both parties.

The billionaire entrepreneur is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.

WASHINGTON — Factions of the health care system and members of Congress are turning their fire on an oft-maligned part of the drug pricing system — the middlemen who negotiate discounts with drug companies on behalf of health plans.

PBMs argue that the rebates they collect from drug companies in exchange for coverage by a health plan are used to lower premiums.

The celebrity investor has teamed up with a soft-spoken radiologist to tackle the USA’s healthcare crisis – and he has drug industry middlemen squarely in his sights, reports Io Dodds

U.S. Sen. Raphael Warnock just introduced a bill that would cap Americans’ out-of-pocket spending on insulin at $35 a month. The legislation would be a godsend to patients battling diabetes. Many of them currently face hundreds of dollars in monthly out-of-pocket costs — an unaffordable burden for many low- and…